We thank Gianfranco Ferraccioli and colleagues, Brandon Reines and colleagues, and Hisyovi Cárdenas Suri for their comments on our Viewpoint[@bib1] discussing the diffuse, alveolar-centred inflammation that triggers immunothrombosis in the lung microvasculature of patients with COVID-19 pneumonia.

Ferraccioli and colleagues posit the role of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection of angiotensin-converting enzyme 2 (ACE2)-expressing endothelial cells in driving this immunothrombosis and other systemic COVID-19 manifestations, including cardiac, neurological, and occasional cutaneous features. It is worth noting that other respiratory viral infections, including severe acute respiratory syndrome, resulted in a similarly high degree of pulmonary intravascular coagulopathy.[@bib2] Since there is no compelling evidence of cardiac endothelial damage, we favour the pulmonary intravascular coagulopathy model, particularly as thrombosis is predominantly observed within the lungs. Nevertheless, ACE2 expression on endothelial cells, detection of SARS-CoV-2 in the endothelium by electron microscopy, juxtaposition of infected alveoli, and reported circulatory viral RNAaemia support the importance of endothelium in pulmonary intravascular coagulopathy. Ferraccioli and colleagues further highlight the pivotal role of endothelium in experimental murine influenza, and that use of a sphingosine-1-phosphate agonist improved survival. However, we can point to other influenza murine models in which similar therapies worsened survival.[@bib3]

We also note the comments on neutrophil extracellular trap formation, or NETosis, and pulmonary vasculature megakaryocytes as potential contributors to pulmonary thrombosis. These factors might indeed be important but they do not detract from our central concept of pulmonary intravascular coagulopathy driven by initial infection of ACE2-expressing pneumocytes in SARS-CoV-2 infection.

Reines and colleagues argue for a new conceptual framework to understand COVID-19 disease and believe that use of the term diffuse is incorrect. We used this term to reflect the extensive and widespread lung involvement typically seen in patients with severe COVID-19. Given the large surface area of the lungs, together with the close juxtaposition of endothelium to pneumocytes, a vast territory for triggering immunothrombosis exists. We acknowledge that other pathological factors, including those relating to type 2 pneumocyte and surfactant biology, might contribute to the disease pathophysiology but these considerations are beyond the remit of our Viewpoint, which is to highlight how a pulmonary intravascular coagulopathy with secondary pulmonary hypertension accounts for mortality in some groups. As indicated in our Viewpoint and previous publications,[@bib4] it seems highly probable that multiple mechanisms contribute to the pulmonary intravascular coagulopathy, which clearly diverges from the classic macrophage activation syndrome pattern typically observed in rheumatology practice.

Hisyovi Cárdenas Suri points out that critically ill patients with COVID-19 might actually be developing a catastrophic antiphospholipid antibody syndrome and that antiphospholipid antibodies should be checked in an effort to improve the management of these patients. In a cohort of 56 patients, 25 (45%) were reported to be positive for lupus anticoagulant.[@bib5] Crucially, however, whether these antiphospholipid antibodies are transient or persistent in nature, or whether they play any pathological role in the development of thrombi within the lung microvasculature, is not known at this stage. Pending the results of further studies to address these key questions, we consider it premature to implicate catastrophic antiphospholipid antibody syndrome in the aetiology underpinning pulmonary intravascular coagulopathy in severe COVID-19.
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